

Agile Therapeutics Third Quarter 2021 Earnings Call


November 2, 2021

Forward-Looking Statements


Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include “forward-looking statements.” We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla®, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures and our expected financing needs and sources of financing, including our debt financing from Perceptive Advisors. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of Twirla, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully commercialize Twirla, the accuracy of our estimates of the potential market for Twirla, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla, our strategy, business plans and focus, the effects of the COVID-19 pandemic on our operations and the operations of third parties we rely upon as well as on our potential customer base, our ability to meet or exceed the revenue thresholds necessary to permit us to access the remaining amount available under our existing debt financing from Perceptive Advisors and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. These factors could cause actual results and developments to be materially different from those expressed in or implied by such statements. These forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Twirla Performance Update

Twirla Growth Based on Key Performance Metrics (Quarterly)



Growing Number of Twirla Prescribers (Quarterly)



Growth Acceleration Initiatives

A Focus on Building and Growing Our Business

pandia
health



myMedi-Cal
How to Get the Health Care You Need



Twirla Branded Influencer Program



BuzzFeed



Carli Lloyd Corporate Partnership

AGILE THERAPEUTICS APPOINTS JOSEPHINE TORRENTE TO ITS BOARD OF DIRECTORS

October 8, 2021

[PDF Version](#)

PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Josephine Torrente has been appointed to the Company's board of directors, as a Class II director, effective as of October 7, 2021. Ms. Torrente will serve on Agile's Science and Technology Committee and Nominating and Corporate Governance Committee.

AGILE THERAPEUTICS APPLAUDS CONGRESSIONAL CHAIRS' LETTER TO BIDEN ADMINISTRATION REQUESTING ENFORCEMENT OF CONTRACEPTIVE ACCESS UNDER AFFORDABLE CARE ACT

October 12, 2021

[PDF Version](#)

PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today applauded House Congressional Committee leaders in urging the Secretaries of U.S. Departments of Health and Human Services (HHS), Treasury, and Labor to enforce the Law regarding women's access to contraceptive methods as dictated by the Affordable Care Act (ACA).

Financial Outlook & Update

Financial Update & Company Outlook

Third Quarter 2021 Results

- Net product sales revenue of \$1.3 million
 - Gross to net revenue allowances increased
- Total expenses of \$14.4 million
 - Remain focused on disciplined spending approach

Near-Term Outlook

- Going forward, we expect product sales revenue to closely track to prescription demand and wholesaler restocking should then more closely reflect retail demand

Financial Flexibility

- \$14.7 million cash and cash equivalents as of Sept. 30, 2021.
- Recently raised an additional \$21.1 million in a public offering

Q&A

Closing Remarks

Q3 2021 Update Call Key Takeaways

- ▶ Approved product that continues to grow in a multi-billion-dollar market
- ▶ Cash on-hand to support the business and anticipate that as we accelerate sales growth our optics on revenue growth will become clearer and allow us to better define the path to profitability
- ▶ Partnerships and programs in place that we believe can accelerate growth